Yes, Exelon Patch can be combined with some other dementia treatments, including memantine for certain people with Alzheimer's disease. However, combinations do not always improve symptoms and may increase risks, so a prescriber should review them first. Exelon Patch is rivastigmine delivered through the skin. Evidence supports selected combinations, but it does not support adding another dementia medicine without an individualized review.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which types of dementia does the evidence cover?
- Can Exelon Patch be taken with memantine?
- What about anti-amyloid treatment?
- Which combinations require particular caution?
- What should patients and caregivers do?
Which types of dementia does the evidence cover?
The diagnosis matters because combination evidence does not apply to every cause of dementia. According to the FDA's May 2024 Exelon Patch label, the patch is indicated for mild, moderate, or severe Alzheimer's dementia and mild-to-moderate Parkinson's disease dementia.
Most direct combination evidence concerns Alzheimer's disease. A person with another form of dementia should not assume that the same potential benefits or risks apply.
Can Exelon Patch be taken with memantine?
Yes. Novartis's FDA-approved prescribing information reports that about 27% of participants in a 48-week rivastigmine patch-dose trial took memantine throughout the study. However, safe co-use does not necessarily mean additional benefit.
In a 24-week randomized open-label trial of 172 people with mild-to-moderate Alzheimer's disease, the combination produced similar overall efficacy, safety, and tolerability results compared with the patch alone. The published study abstract reported no efficacy advantage from adding memantine. Because participants and researchers knew which treatment was given, and the trial was modest in size, it may have missed smaller differences. A later 24-week study of 147 people also found no significant agitation benefit from adding memantine.
What about anti-amyloid treatment?
Lecanemab trials enrolled people who either were or were not taking a cholinesterase inhibitor or memantine, according to the FDA's 2026 Leqembi label. This confirms that background dementia medicines were permitted during those trials.
It does not establish that Exelon Patch and disease-modifying therapy are appropriate for every individual. Trial co-use should not replace a review of the person's diagnosis, current medicines, and treatment plan.
Which combinations require particular caution?
The medication review must extend beyond dementia drugs. The DailyMed prescribing information identifies several important interactions: These concerns do not mean every listed medicine must automatically be stopped. They mean the prescriber must weigh the reason for each drug against the interaction risk.
- Other medicines with cholinomimetic effects can intensify rivastigmine's cholinergic effects.
- Anticholinergic medicines, including oxybutynin and tolterodine, can work against rivastigmine unless a clinician considers the combination necessary.
- Beta-blockers can add to rivastigmine's heart-rate-lowering effect and cause fainting. The combination is not recommended when slow heart rate or fainting is present.
- Metoclopramide is not recommended because the combination can increase movement-related adverse effects.
What should patients and caregivers do?
Before adding, stopping, or changing treatment: Caregivers should also check the skin before applying each dose. Remove the old Exelon Patch before placing a new one because accidentally wearing multiple patches has caused hospitalization and, rarely, death.
- Give the prescriber and pharmacist a complete list of prescriptions, nonprescription medicines, and patches.
- Confirm the dementia diagnosis and severity.
- Discuss what improvement the added medicine is expected to produce.
- Agree on how nausea, vomiting, diarrhea, appetite or weight loss, dizziness, fainting, and skin reactions will be monitored.
